Toll Free: 1-888-928-9744

Incyte Corporation - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Incyte Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Incyte Corporation - Product Pipeline Review - 2014', provides an overview of the Incyte Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Incyte Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Incyte Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Incyte Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Incyte Corporation's pipeline products

Reasons to buy

- Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Incyte Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Incyte Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Incyte Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Incyte Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Incyte Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Incyte Corporation Snapshot 5
Incyte Corporation Overview 5
Key Information 5
Key Facts 5
Incyte Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Incyte Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Incyte Corporation - Pipeline Products Glance 14
Incyte Corporation - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Incyte Corporation - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Incyte Corporation - Drug Profiles 17
ruxolitinib phosphate 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
INCB-047986 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
INCB-24360 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
INCB-39110 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drug for Chronic Inflammatory Condition 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Drugs for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INCB-040093 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
INCB-050465 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules for Inflammation 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Incyte Corporation - Pipeline Analysis 31
Incyte Corporation - Pipeline Products by Target 31
Incyte Corporation - Pipeline Products by Route of Administration 32
Incyte Corporation - Pipeline Products by Molecule Type 33
Incyte Corporation - Pipeline Products by Mechanism of Action 34
Incyte Corporation - Recent Pipeline Updates 35
Incyte Corporation - Dormant Projects 46
Incyte Corporation - Discontinued Pipeline Products 48
Discontinued Pipeline Product Profiles 48
aderbasib 48
INCB-15050 48
INCB-8696 48
INCB-9471 48
Incyte Corporation - Company Statement 49
Incyte Corporation - Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
List of Tables
Incyte Corporation, Key Information 5
Incyte Corporation, Key Facts 5
Incyte Corporation - Pipeline by Indication, 2014 7
Incyte Corporation - Pipeline by Stage of Development, 2014 10
Incyte Corporation - Monotherapy Products in Pipeline, 2014 11
Incyte Corporation - Out-Licensed Products in Pipeline, 2014 12
Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Incyte Corporation - Phase III, 2014 14
Incyte Corporation - Phase II, 2014 15
Incyte Corporation - Phase I, 2014 16
Incyte Corporation - Pipeline by Target, 2014 31
Incyte Corporation - Pipeline by Route of Administration, 2014 32
Incyte Corporation - Pipeline by Molecule Type, 2014 33
Incyte Corporation - Pipeline Products by Mechanism of Action, 2014 34
Incyte Corporation - Recent Pipeline Updates, 2014 35
Incyte Corporation - Dormant Developmental Projects,2014 46
Incyte Corporation - Discontinued Pipeline Products, 2014 48
Incyte Corporation, Subsidiaries 52 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify